{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-022160","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.595296+00:00","generated_at":"2026-06-23T11:07:46.126117+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"UroGen appoints Dr. Leana Wen to board and audit committee","bullets":["Dr. Wen appointed to fill vacancy; term runs until 2023 annual meeting.","Received initial option for 20,000 ordinary shares vesting quarterly over 12 quarters.","Annual retainer of $40,000 for board service plus $7,500 for audit committee.","Eligible for annual option grant of 10,000 ordinary shares at each shareholder meeting.","Company entered standard director indemnity agreement with Dr. Wen."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-022160","json":"https://secwatch.observer/filing/0001437749-22-022160.json","markdown":"https://secwatch.observer/filing/0001437749-22-022160.md","text":"https://secwatch.observer/filing/0001437749-22-022160.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922022160/0001437749-22-022160-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922022160/urgn20220909_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:07:46.126117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89aac55d59","claim":"Leana Wen was appointed as Director at UroGen Pharma Ltd..","evidence_excerpt":"On September 8, 2022, Leana Wen, M.D., MSc was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders and was also appointed to the Audit Committee of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922022160/0001437749-22-022160-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}